Powered 500 · 2026POWEREDS. 014 of 500
Schleifer founded Regeneron in 1988 and has spent 35-plus years building it into a $13 billion biotech giant whose drugs — Dupixent, Eylea, and REGEN-COV — now treat millions across allergies, blindness, cancer, and COVID-19.
Leonard Schleifer is the Founder, President, and CEO of Regeneron Pharmaceuticals, one of the most successful biotechnology companies in the world with over $13 billion in annual revenue.
Schleifer founded Regeneron in 1988 with George Yancopoulos and has led the company for over 35 years-one of the longest tenures of any founder-CEO in biotech. Regeneron's portfolio includes blockbuster drugs such as Eylea (for eye diseases), Dupixent (for eczema and asthma), and Libtayo (for cancer), as well as the REGEN-COV antibody cocktail that was used to treat COVID-19. The company's VelociSuite technology platform has dramatically accelerated the process of discovering and developing new medicines. Schleifer's leadership combines deep scientific understanding with business acumen-he holds both an MD and a PhD. Under his guidance, Regeneron has consistently produced breakthrough medicines while maintaining a culture of scientific rigor and innovation. His nearly four decades of founder-CEO leadership in biotech is virtually unmatched.
Interview · In Pipeline
Sponsored placement
An invitation, extended to Powered readers.
Drive the Continental GT S.
Request a test driveBentley T&Cs apply
